Patients receiving allogeneic hematopoietic cell transplantation (HCT) have high morbidity and mortality risk, but literature is limited on factors associated with end-of-life (EOL) care intensity.
Objectives:
Describe EOL care in patients after allogeneic HCT and examine association of patient and clinical characteristics with intense EOL care.
Design:
Retrospective chart review.
Setting/Subjects:
A total of 113 patients who received allogeneic HCT at Mayo Clinic Arizona between 2013 and 2017 and died before November 2019.
Measurements:
A composite EOL care intensity measure included five markers: (1) no hospice enrollment, (2) intensive care unit (ICU) stay in the last month, (3) hospitalization >14 days in last month, (4) chemotherapy use in the last two weeks, and (5) cardiopulmonary resuscitation, hemodialysis, or mechanical ventilation in the last week of life. Multivariable logistic regression modeling assessed associations of having ≥1 intensity marker with sociodemographic and disease characteristics, palliative care consultation, and advance directive documentation.
Results:
Seventy-six percent of patients in our cohort had ≥1 intensity marker, with 43% receiving ICU care in the last month of life. Median hospital stay in the last month of life was 15 days. Sixty-five percent of patients died in hospice; median enrollment was 4 days. Patients with higher education were less likely to have ≥1 intensity marker (odds ratio 0.28, p = 0.02). Patients who died >100 days after HCT were less likely to have ≥1 intensity marker than patients who died ≤100 days of HCT (p = 0.04).
Conclusions:
Death within 100 days of HCT and lower educational attainment were associated with higher likelihood of intense EOL care.
Get full access to this article
View all access options for this article.
References
1.
D'SouzaA, LeeS, ZhuX, PasquiniM: Current use and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant, 2017; 23:1417–1421.
2.
ZhangB, WrightAA, HuskampHA, et al.: Health care costs in the last week of life. Arch Intern Med, 2009; 169:480.
3.
GarridoMM, PrigersonHG, BaoY, MaciejewskiPK: Chemotherapy use in the months before death and estimated costs of care in the last week of life. J Pain Symptom Manage, 2016; 51:875.e2–881.e2.
4.
LangtonJM, BlanchB, DrewAK, et al.: Retrospective studies of end-of-life resource utilization and costs in cancer care using health administrative data: A systematic review. Palliat Med, 2014; 28:1167–1196.
5.
PrigersonHG, BaoY, ShahMA, et al.: Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncol, 2015; 1:778–784.
6.
WrightAA, MackJW, KritekPA, et al.: Influence of patients' preferences and treatment site on cancer patients' end-of-life care. Cancer, 2010; 116:4656–4663.
7.
HowellDA, WangHI, RomanE, et al.: Preferred and actual place of death in haematological malignancy. BMJ Support Palliat Care, 2017; 7:150–157.
8.
McGrathP: Caregivers' insights on the dying trajectory in hematology oncology. Cancer Nurs, 2001; 24:413–421.
9.
McGrathP: Qualitative findings on the experience of end-of-life care for hematological malignancies. Am J Hosp Palliat Med, 2002; 19:103–111.
10.
NilssonJ, BlombergC, HolgerssonG, et al.: End-of-life care: Where do cancer patients want to die? A systematic review. Asia Pac J Clin Oncol, 2017; 13:356–364.
11.
WrightAA, KeatingNL, AyanianJZ, et al.: Family perspectives on aggressive cancer care near the end of life. J Am Med Assoc, 2016; 315:284–292.
12.
WrightAA, ZhangB, RayA, et al.: Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. J Am Med Assoc, 2008; 300:1665–1673.
13.
American Society of Clinical Oncology: QOPI ® 2018 REPORTING TRACKS. 2018.
14.
OdejideOO, CroninAM, CondronNB, et al.: Barriers to quality end-of-life care for patients with blood cancers. J Clin Oncol, 2016; 34:3126–3132.
15.
OdejideOO, Salas CoronadoDY, WattsCD, et al.: End-of-life care for blood cancers: A series of focus groups with hematologic oncologists. J Oncol Pract, 2014; 10:e396–e403.
16.
CappellK, SundaramV, ParkA, et al.: Advance directive utilization is associated with less aggressive end-of-life care in patients undergoing allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant, 2018; 24:1035–1040.
17.
EckhertEE, SchoenbeckKL, GalliganD, et al.: Advance care planning and end-of-life care for patients with hematologic malignancies who die after hematopoietic cell transplant. Bone Marrow Transplant, 2017; 52:929–931.
18.
KirtaneK, DowneyL, LeeSJ, et al.: Intensity of end-of-life care for patients with hematologic malignancies and the role of race/ethnicity. J Palliat Med, 2018; 21:1466–1471.
19.
HoTH, BarberaL, SaskinR, et al.: Trends in the aggressiveness of end-of-life cancer care in the universal health care system of Ontario, Canada. J Clin Oncol, 2011; 29:1587–1591.
20.
TangST, WuSC, HungYN, et al.: Determinants of aggressive end-of-life care for Taiwanese cancer decedents, 2001 to 2006. J Clin Oncol, 2009; 27:4613–4618.
21.
HuiD, DidwaniyaN, VidalM, et al.: Quality of end-of-life care in patients with hematologic malignancies: A retrospective cohort study. Cancer, 2014; 120:1572–1578.
22.
LangstonJA, SundaramV, PeriyakoilVS, MufflyL: Healthcare utilization is high in adult patients relapsing after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant, 2019; 25:1659–1665.
23.
LeBlancTW: Palliative care and hematologic malignancies: Old dog, new tricks?. J Oncol Pract, 2014; 10:e404–e407.
24.
FletcherSA, CroninAM, ZeidanAM, et al.: Intensity of end-of-life care for patients with myelodysplastic syndromes: Findings from a large national database. Cancer, 2016; 122:1209–1215.
25.
WangWS, MaJD, NelsonSH, et al.: Transfusion practices at end of life for hematopoietic stem cell transplant patients. Support Care Cancer, 2018; 26:1927–1931.
26.
MannisGN, McNeyLM, GuptaNK, GrossDM: The transfusion tether: Bridging the gap between end-stage hematologic malignancies and optimal end-of-life care. Am J Hematol, 2016; 91:364–365.
27.
LeBlancTW, EganPC, OlszewskiAJ: Transfusion dependence, use of hospice services, and quality of end-of-life care in leukemia. Blood, 2018; 132:717–726.
28.
SexauerA, ChengMJ, KnightL, et al.: Patterns of hospice use in patients dying from hematologic malignancies. J Palliat Med, 2014; 17:195–199.
29.
WangR, ZeidanAM, HaleneS, et al.: Health care use by older adults with acute myeloid leukemia at the end of life. J Clin Oncol, 2017; 35:3417–3424.
30.
El-JawahriAR, AbelGA, SteensmaDP, et al.: Health care utilization and end-of-life care for older patients with acute myeloid leukemia. Cancer, 2015; 121:2840–2848.
31.
HowellDA, RomanE, CoxH, et al.: Destined to die in hospital? Systematic review and meta-analysis of place of death in haematological malignancy. BMC Palliat Care, 2010; 9:9.
32.
HowellDA, ShellensR, RomanE, et al.: Haematological malignancy: Are patients appropriately referred for specialist palliative and hospice care? A systematic review and meta-analysis of published data. Palliat Med, 2011; 25:630–641.
33.
FadulN, ElsayemA, PalmerJL, et al.: Predictors of access to palliative care services among patients who died at a comprehensive cancer center. J Palliat Med, 2007; 10:1146–1152.
34.
ChengHB, LiC, ChanK, et al.: End-of-life characteristics and palliative care provision for elderly patients suffering from acute myeloid leukemia. Support Care Cancer, 2015; 23:111–116.
35.
BeaussantY, DaguindauE, ChauchetA, et al.: Hospital end-of-life care in haematological malignancies. BMJ Support Palliat Care, 2018; 8:314–324.
36.
O'ConnorNR, HuR, HarrisPS, et al.: Hospice admissions for cancer in the final days of life: Independent predictors and implications for quality measures. J Clin Oncol, 2014; 32:3184–3189.
37.
LeBlancTW, AbernethyAP, CasarettDJ: What is different about patients with hematologic malignancies? A retrospective cohort study of cancer patients referred to a Hospice Research Network. J Pain Symptom Manage, 2015; 49:505–512.
38.
LinRJ, ElkoTA, PeralesM-A, et al.: End-of-life care for older AML patients relapsing after allogeneic stem cell transplant at a dedicated cancer center. Bone Marrow Transplant, 2019; 54:700–706.
39.
JohnstonEE, MufflyL, SayninaO, et al.: End-of-life care intensity in patients undergoing allogeneic hematopoietic cell transplantation: A population-level analysis. J Clin Oncol, 2018; 36:3023–3030.
40.
SnamanJM, TalleurAC, LuJ, et al.: Treatment intensity and symptom burden in hospitalized adolescent and young adult hematopoietic cell transplant recipients at the end of life. Bone Marrow Transplant, 2018; 53:84–90.
41.
HanH, LiuY, QinY, et al.: Utilization of palliative care for patients undergoing hematopoietic stem cell transplantation during hospitalization: A population-based national study. Am J Hosp Palliat Med, 2019; 36:900–906.
42.
WangWS, MaJD, NelsonSH, et al.: Advance care planning and palliative care integration for patients undergoing hematopoietic stem-cell transplantation. J Oncol Pract, 2017; 13:e721–e728.
43.
HartogCS, PeschelI, SchwarzkopfD, et al.: Are written advance directives helpful to guide end-of-life therapy in the intensive care unit? A retrospective matched-cohort study. J Crit Care, 2014; 29:128–133.
44.
WallaceSK, MartinCG, ShawAD, PriceKJ: Influence of an advance directive on the initiation of life support technology in critically ill cancer patients. Crit Care Med, 2001; 29:2294–2298.
45.
HuiD, KimSH, RoquemoreJ, et al.: Impact of timing and setting of palliative care referral on quality of end-of-life care in cancer patients. Cancer, 2014; 120:1743–1749.
46.
MackJW, ChenLH, CannavaleK, et al.: End-of-life care intensity among adolescent and young adult patients with cancer in Kaiser Permanente Southern California. JAMA Oncol, 2015; 1:592.
47.
McNeeseNJ, KheraN, WordinghamSE, et al.: Team cognition as a means to improve care delivery in critically ill patients with cancer after hematopoietic cell transplantation. J Oncol Pract, 2016; 12:1091–1099.
48.
ButtonE, ChanRJ, ChambersS, et al.: A systematic review of prognostic factors at the end of life for people with a hematological malignancy. BMC Cancer, 2017; 17:213.
49.
McCaughanD, RomanE, SmithAG, et al.: Determinants of hospital death in haematological cancers: Findings from a qualitative study. BMJ Support Palliat Care, 2018; 8:78–86.
50.
McCaughanD, RomanE, SmithAG, et al.: Perspectives of bereaved relatives of patients with haematological malignancies concerning preferred place of care and death: A qualitative study. Palliat Med, 2019; 33:518–530.
51.
El-JawahriA, TemelJS: Palliative care integration in hematopoietic stem-cell transplantation: The need for additional research. J Oncol Pract, 2017; 13:578–579.
52.
OdejideOO, CroninAM, EarleCC, et al.: Why are patients with blood cancers more likely to die without hospice?. Cancer, 2017; 123:3377–3384.
53.
OdejideOO: A policy prescription for hospice care. JAMA, 2016; 315:257.
54.
U.S. Centers for Medicare and Medicaid Services: Medicare care choices model enables concurrent palliative and curative care. J Pain Palliat Care Pharmacother, 2015; 29:401–403.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
